Skip to main content

HIV/AIDS

Infectious Diseases
29
Pipeline Programs
30
Companies
50
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
4
5
3
3
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 114 programs with unclassified modality

Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.

$11.9B marketMature→ Stable30 products15 companies

Key Trends

  • HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
  • Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
  • High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity

Career Verdict

Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1BIKTARVYStable
$3.2B
Gilead Sciences·Peak10.5yr
#2EPCLUSAStable
$877M
Gilead Sciences·Peak8.2yr
#3TIVICAYDeclining
$657M
GSK·Peak4.1yr
#4TRIUMEQDeclining
$632M
GSK·Peak4.1yr
#5GENVOYAStable
$626M
Gilead Sciences·Peak6.9yr

Drug Class Breakdown

Nucleoside Reverse Transcriptase Inhibitors
$5.2B(44%)

backbone of HIV treatment, stable demand

RNA Replicase Inhibitors
$1.8B(15%)

hepatitis C treatment, mature market

Cytochrome P450 3A Inhibitors
$1.4B(12%)

boosting agents in combination regimens

P-Glycoprotein Inhibitors
$343M(3%)

niche mechanism, limited growth

Career Outlook

Stable

Infectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.

Breaking In

Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.

For Experienced Professionals

Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.

In-Demand Skills

Market access and payer strategyBrand management in generic-transition environmentsManufacturing scale-up and supply chain optimizationMedical science liaison (MSL) capabilities for physician engagementHealth economics and real-world outcomes analysis

Best For

Brand ManagerMarket Access ManagerMedical Science LiaisonSales DirectorManufacturing EngineerHealth Economics Analyst

Hiring Landscape

$160K–$275K

Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.

780
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

214Growing
100Stable
61Stable
51Growing

By Department

Commercial(32%)
$275K
Engineering(16%)
$237K
Manufacturing(14%)
$160K
Research & Development(9%)
$184K

Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.

Competitive Landscape

32 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
13 programs
1
1
2
5
Digital Health Feedback SystemPhase 41 trial
Digital pillPhase 41 trial
Emtricitabine and TenofovirPhase 4Small Molecule1 trial
Enhanced PrEP AdherencePhase 41 trial
bictegravir/emtricitabine/tenofovir alafenamidePhase 41 trial
+8 more programs
Active Trials
NCT03405194Withdrawn0Est. Jul 2020
NCT03343223Completed234Est. Feb 2019
NCT05111119Completed53Est. Aug 2024
+9 more trials
ViiV Healthcare
ViiV HealthcareNC - Durham
5 programs
1
Digital Health Feedback SystemPhase 4
Alert to providerN/A
Cabotegravir InjectionN/A
Proviral DNA as a Target for HIV-1 Resistance AnalysisN/A
Reengagement and Assessment Mobile ProgramN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
5 programs
1
1
bictegravir/emtricitabine/tenofovir alafenamidePhase 4
Darunavir/CobicistatPhase 2/3Small Molecule1 trial
Digital PillN/A
Quantifying Drug Adherence and Drug Exposure to Antiretroviral TherapyN/A1 trial
SOC-REC/SOC-OICN/A1 trial
Active Trials
NCT02012621Completed807Est. Jul 2017
NCT04432571Active Not Recruiting880Est. Dec 2025
NCT02499978Withdrawn0Est. Jun 2016
Human BioSciences
Human BioSciencesWV - Martinsburg
15 programs
2
1
EfavirenzPhase 31 trial
SMART PackPhase 11 trial
Tenofovir DouchePhase 11 trial
ACTN/A1 trial
ActivitiesN/A1 trial
+10 more programs
Active Trials
NCT03152006Unknown216Est. Jun 2021
NCT07072481Recruiting1,216Est. Aug 2028
NCT03875950Completed232Est. Dec 2021
+9 more trials
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
MetforminPhase 2/31 trial
Active Trials
NCT04500678Unknown38Est. Dec 2022
MSD
MSDIreland - Ballydine
1 program
1
MetforminPhase 2/3
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
13 programs
2
1
1
Biktarvy®Phase 21 trial
Combination InterventionPhase 1/21 trial
Tenofovir DouchePhase 11 trial
Tenofovir douchePhase 11 trial
Adolescent Master ProtocolN/A1 trial
+8 more programs
Active Trials
NCT01418014Completed678Est. Feb 2021
NCT02119702Completed818Est. May 2025
NCT03279185Completed334Est. May 2025
+10 more trials
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
8 programs
1
1
ISS-SBDOH armPhase 21 trial
Switch to E/C/FTC/TAF dailyPhase 1/21 trial
Combined Contingency Management and Peer NavigationN/A1 trial
Daily IVR Calls InterventionN/A1 trial
HHMBN/A1 trial
+3 more programs
Active Trials
NCT02310893Completed579Est. Jan 2020
NCT02118454Completed400Est. Mar 2015
NCT04025463Completed202Est. May 2023
+5 more trials
Innovation Pharmaceuticals
3 programs
1
ISS-SBDOH armPhase 2
Link2CAREN/A1 trial
Three month dispensing of ART in CARGsN/A1 trial
Active Trials
NCT03369249Completed307Est. Dec 2022
NCT03238846Unknown4,676Est. Sep 2019
Response Pharmaceuticals
Response PharmaceuticalsVA - Falls Church
2 programs
1
REMUNEPhase 21 trial
Option B+N/A1 trial
Active Trials
NCT01891799Completed2,518Est. Oct 2016
NCT02291809Unknown26Est. Nov 2019
GeoVax
GeoVaxGA - Smyrna
1 program
1
Combination InterventionPhase 1/2
Achilles Therapeutics
2
medroxyprogesterone acetatePhase 1
tenofovir/emtricitabinePhase 11 trial
Active Trials
NCT03197961Completed15Est. Dec 2020
Pfizer
PfizerNEW YORK, NY
1 program
1
MaravirocPhase 11 trial
Active Trials
NCT00775294Completed14Est. Mar 2010
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
13 programs
Intervention GroupN/A
Intervention GroupN/A
Making PrEP SmartN/A
Making PrEP SmartN/A
P4P interventionN/A
+8 more programs
GSK
GSKLONDON, United Kingdom
5 programs
Alert to providerN/A1 trial
Cabotegravir InjectionN/A1 trial
Proviral DNA as a Target for HIV-1 Resistance AnalysisN/A1 trial
Reengagement and Assessment Mobile ProgramN/A1 trial
Digital Health Feedback SystemPHASE_4
Active Trials
NCT04147832Completed10,521Est. Jul 2021
NCT05949203Unknown125Est. Dec 2025
NCT04088916Unknown1,200Est. Dec 2022
+1 more trials
UNION therapeutics
Efavirenz 400Mg Oral TabletN/A1 trial
Lpv/r+3TCN/A1 trial
The Evaluations of Cardiovascular Changes in Long-term Treated HIV-infected IndividualsN/A1 trial
rapid HIV and HCV serological testsN/A1 trial
Active Trials
NCT04463784Unknown500Est. Aug 2021
NCT03603977Recruiting600Est. Oct 2030
NCT04463810Unknown500Est. Sep 2021
+1 more trials
Temple Therapeutics
Black Men's CareN/A1 trial
Enhanced InterventionN/A1 trial
Risk reduction behavioral interventionN/A1 trial
Active Trials
NCT03579251Completed28Est. Jun 2024
NCT03541642Completed35Est. Dec 2021
NCT03048838Unknown300Est. Apr 2020
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
3 programs
Cabotegravir InjectionN/A
Enhanced implementation of PrEPN/A1 trial
We TestN/A1 trial
Active Trials
NCT03992274Terminated114Est. Sep 2023
NCT04289116Completed71Est. May 2022
Relief Therapeutics
Relief TherapeuticsSwitzerland - Geneva
2 programs
Community score card approachN/A1 trial
PrEP CohortN/A
Active Trials
NCT04372667Completed1,233Est. Mar 2019
Bristol Myers Squibb
2 programs
EfavirenzN/A1 trial
Impact of Hyperbilirubinemia Among HIV Patients Treated With AtazanavirN/ASmall Molecule1 trial
Active Trials
NCT02426866Completed29,612Est. Jan 2015
NCT02532673Completed1,200Est. May 2015
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
Enhanced Peer InterventionN/A1 trial
Patient NavigationN/A1 trial
Active Trials
NCT01616940CompletedEst. Mar 2014
NCT02259634TerminatedEst. Apr 2015
Impact Therapeutics
Impact TherapeuticsChina - Shanghai
2 programs
Inter-personal CommunicationN/A1 trial
Prize-linked savingsN/A1 trial
Active Trials
NCT02497989Completed2,785Est. Jan 2016
NCT04013295Completed300Est. Dec 2018
Autonomous Therapeutics
2 programs
Interactive Communication with Openness, Passion, and Empowerment "ICOPE"N/A1 trial
PLWH interventionN/A1 trial
Active Trials
NCT04051177Completed791Est. Dec 2018
NCT05174936Active Not Recruiting1,928Est. Nov 2027
Aurum Biosciences
Aurum BiosciencesUK - Glasgow
1 program
Choice ArchitectureN/A1 trial
Active Trials
NCT04466293Completed57Est. Oct 2022
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
Door-to-doorN/A1 trial
Active Trials
NCT01459120Completed1,800Est. Feb 2012
Checkpoint Therapeutics
1 program
Harm reduction of informal PrEP useN/A1 trial
Active Trials
NCT03996941Unknown900Est. Sep 2024
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Integrated Community-BasedN/A1 trial
Active Trials
NCT04417127Completed1,200Est. Dec 2023
Young BioPharma
Young BioPharmaMA - Lowell
1 program
LYNXN/A
Alliance Pharmaceuticals
1 program
Medication optimization interventionN/A1 trial
Active Trials
NCT03437694Terminated129Est. Feb 2025
Cipher Pharmaceuticals
Cipher PharmaceuticalsON - Mississauga
1 program
PEBRA modelN/A1 trial
Active Trials
NCT03969030CompletedEst. Apr 2021

+2 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Kite Pharmabictegravir/emtricitabine/tenofovir alafenamide
Kite PharmaDigital Health Feedback System
Kite PharmaDigital pill
Kite PharmaEmtricitabine and Tenofovir
Kite PharmaEnhanced PrEP Adherence
Kite PharmaTDF/FTC 300mg/200mg fixed-dose combination tablets
Kite PharmaBiktarvy
Human BioSciencesEfavirenz
Sharp TherapeuticsMetformin
Colorado TherapeuticsDarunavir/Cobicistat
Angeles TherapeuticsISS-SBDOH arm
Allergy TherapeuticsBiktarvy®
Kite PharmaChAdOx1.HTI
Response PharmaceuticalsREMUNE
Allergy TherapeuticsCombination Intervention

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 318,136 patients across 50 trials

NCT04249037Kite Pharmabictegravir/emtricitabine/tenofovir alafenamide

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

Start: Dec 2020Est. completion: Jul 202310 patients
Phase 4Terminated
NCT04418037Kite PharmaDigital Health Feedback System

DHFS for Medication Adherence Support During Hospital Admissions for Person Living With HIV

Start: May 2019Est. completion: Dec 202116 patients
Phase 4Completed

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

Start: Oct 2018Est. completion: Apr 202016 patients
Phase 4Completed
NCT03120494Kite PharmaEmtricitabine and Tenofovir

Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B

Start: Nov 2016Est. completion: Nov 201975 patients
Phase 4Unknown
NCT02167386Kite PharmaEnhanced PrEP Adherence

PrEPared and Strong: Clinic-Based PrEP for Black MSM

Start: Mar 2015Est. completion: Feb 2018204 patients
Phase 4Completed
NCT05813964Kite PharmaTDF/FTC 300mg/200mg fixed-dose combination tablets

Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

Start: Jun 2024Est. completion: May 2027524 patients
Phase 3Recruiting

The Late Presenter Treatment Optimisation Study

Start: Mar 2019Est. completion: Jun 2024447 patients
Phase 3Completed

Treatment Options for Protease Inhibitor-exposed Children

Start: Jul 2010Est. completion: Dec 2014300 patients
Phase 3Completed

Impact of Metformin on Immuno-virologic Parameters in HIV

Start: Feb 2019Est. completion: Dec 202238 patients
Phase 2/3Unknown

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity

Start: May 2016Est. completion: Jun 20160
Phase 2/3Withdrawn

An Integrated Intervention Using a Pill Ingestible Sensor System

Start: Dec 2024Est. completion: Jul 2027110 patients
Phase 2Recruiting

INSTI's For The Management of HIV-associated TB

Start: Feb 2022Est. completion: Aug 2024122 patients
Phase 2Completed

Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

Start: Feb 2020Est. completion: Dec 202250 patients
Phase 2Completed

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

Start: Nov 2017Est. completion: Nov 201926 patients
Phase 2Unknown
NCT04357821Allergy TherapeuticsCombination Intervention

Combinatorial Therapy to Induce an HIV Remission

Start: Aug 2020Est. completion: Jun 202611 patients
Phase 1/2Active Not Recruiting
NCT03251144Angeles TherapeuticsSwitch to E/C/FTC/TAF daily

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

Start: Apr 2019Est. completion: Jul 202126 patients
Phase 1/2Completed

Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse

Start: Jun 2021Est. completion: Dec 20226 patients
Phase 1Completed

Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)

Start: Apr 2021Est. completion: Nov 20228 patients
Phase 1Completed

Tenofovir Rectal Douche to Prevent HIV Transmission

Start: Jan 2020Est. completion: Apr 20219 patients
Phase 1Completed

Innovative Tools to Expand HIV Self-Testing

Start: Jul 2019Est. completion: Sep 2020388 patients
Phase 1Completed
NCT03197961Achilles Therapeuticstenofovir/emtricitabine

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

Start: Nov 2017Est. completion: Dec 202015 patients
Phase 1Completed
NCT02346084Allergy TherapeuticsMaraviroc 300 mg tablet

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

Start: Jan 2015Est. completion: Mar 201619 patients
Phase 1Completed

Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue

Start: May 2008Est. completion: Mar 201014 patients
Phase 1Completed

Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing

Start: Oct 2025Est. completion: Aug 20281,216 patients
N/ARecruiting

MyPEEPS LITE Trial

Start: Jan 2025Est. completion: Dec 20283,200 patients
N/ARecruiting
NCT06347146Human BioSciencesFinancial Literacy Training

Bridges2Scale: Testing Implementation Strategies

Start: Jun 2024Est. completion: Jul 20281,440 patients
N/AActive Not Recruiting

Targeted Universal TB Testing With Simultaneous TPT Prescribing Among People Living With HIV in South Africa

Start: May 2024Est. completion: Jun 2025414 patients
N/ACompleted
NCT06353295Kite PharmaP4P intervention

Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study

Start: Apr 2024Est. completion: Jun 2026140 patients
N/AActive Not Recruiting
NCT05949203GSKCabotegravir Injection

Oregon PrEP at Home Study

Start: Dec 2023Est. completion: Dec 2025125 patients
N/AUnknown

ResIlience-based Stigma REdUction Program ("Rise-up")

Start: Nov 2023Est. completion: Nov 20271,928 patients
N/AActive Not Recruiting
NCT06528626UNION therapeuticsrapid HIV and HCV serological tests

Tools to Identify People At Risk or Already Infected with HIV and HCV

Start: Jul 2023Est. completion: Dec 2025240,000 patients
N/ARecruiting
NCT05111119Kite PharmaMaking PrEP Smart

Making PrEP Smart: An HIV Testing and PrEP Electronic Support Tool ("SmartPrEP" App) for Women on PrEP

Start: Feb 2022Est. completion: Aug 202453 patients
N/ACompleted

Prevent TB: Choice Architecture for TPT Delivery

Start: Sep 2021Est. completion: Nov 202450,798 patients
N/ACompleted

ADAPT for Adolescents Adolescents

Start: Apr 2021Est. completion: Dec 2025880 patients
N/AActive Not Recruiting
NCT04466293Aurum BiosciencesChoice Architecture

Choice Architecture Based TB Preventive Therapy Prescribing

Start: Mar 2021Est. completion: Oct 202257 patients
N/ACompleted
NCT04341779Allergy TherapeuticsPoint-of-care viral load testing and tenofovir adherence testing

Simplifying Treatment and Monitoring for HIV (STREAM HIV)

Start: Feb 2021Est. completion: Dec 2026539 patients
N/AActive Not Recruiting
NCT04417127Purdue PharmaIntegrated Community-Based

Harambee: Integrated Community-based HIV/NCD Care & Microfinance Groups in Kenya

Start: Nov 2020Est. completion: Dec 20231,200 patients
N/ACompleted
NCT04147832GSKAlert to provider

Epividian / AHF: Positive Pathways - HIV Retention in Care

Start: Oct 2020Est. completion: Jul 202110,521 patients
N/ACompleted
NCT03992274Oregon TherapeuticsEnhanced implementation of PrEP

Biomedical HIV/AIDS Prevention Program Yunnan

Start: Aug 2020Est. completion: Sep 2023114 patients
N/ATerminated
NCT04151498GSKReengagement and Assessment Mobile Program

HIV Reengagement and Assessment Mobile Program (Project RAMP)

Start: May 2020Est. completion: Apr 202330 patients
N/ACompleted

Enhancing Sexual Safety: Couples' Communication and HIV Testing Among YMSM

Start: Jan 2020Est. completion: May 202271 patients
N/ACompleted

Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF)

Start: Nov 2019Est. completion: May 202384 patients
N/ACompleted

Peer-Educator-coordinated vs Nurse-coordinated ART Refill for Adolescents and Young Adults Living With HIV in Lesotho

Start: Nov 2019Est. completion: Apr 2021
N/ACompleted

Comparison of Men's Prevention Apps to Research Efficacy

Start: Oct 2019Est. completion: May 2022381 patients
N/ACompleted

Healing Our Hearts Minds and Bodies: CVD Reduction in Persons With HIV

Start: Oct 2019Est. completion: May 2023202 patients
N/ACompleted
NCT03584932Angeles TherapeuticsLINK2 Youth Services Navigation Intervention

Youth Services Navigation Intervention for HIV+ Youth Being Released From or At-risk for Incarceration

Start: Aug 2019Est. completion: Mar 2024106 patients
N/ACompleted
NCT03996941Checkpoint TherapeuticsHarm reduction of informal PrEP use

Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)

Start: Jul 2019Est. completion: Sep 2024900 patients
N/AUnknown

Evaluation of Pre-Exposure Prophylaxis for High Risk Adolescent Girls and Young Women

Start: Jun 2019Est. completion: Dec 20201,032 patients
N/AUnknown
NCT03875950Human BioSciencesClinician training intervention

Standardized Patient Encounters to Improve PrEP Counseling for Adolescent Girls and Young Women in Kenya

Start: Mar 2019Est. completion: Dec 2021232 patients
N/ACompleted

Depression Intervention Among Gay and Bisexual Men Receiving Treatment for Methamphetamine Use

Start: Feb 2019Est. completion: May 202039 patients
N/ACompleted

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
5 actively recruiting trials targeting 318,136 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.